Resources for Patients and their Families

Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays

Brief Summary

Peritoneal mesothelioma is a rare disease representing one third of all mesothelioma and nothing is known about molecular characteristics of this disease. As main cancers, genetic heterogeneity is probable. This genomic profiling associates Comparative Genomic Hybridization (CGH) array, BAP1 sequencing and gene expression in order to discover a biomarker that could be used in the treatment of this rare disease. Corresponding histopathological and immunohistochemical report as all clinical data are available. All data with be merged to underline a few genes of interest on which we will focus our next investigations. Depending of our preliminary results, BAP1 mutations are expected, as it was also described in pleural mesothelioma. Mutations in oncogenic drivers that could be targeted by specific therapy will be on particular interest in management of this rare disease with bad prognosis.

Tracking Information
First Received DateApril 27, 2016
Last Changed DateJuly 25, 2016
Start DateMay 2013
Actual Primary Completion DateJanuary 2016
Primary Outcome Measures

BAP1 mutations [Time Frame: Day 0]

Descriptive Information
Study TypeObservational
  • Peritoneal Mesothelioma
  • Genetic: comparative genomic analysis
Study Arms / Comparison Groups0 / 1
Recruitment Information
Recruitment StatusCompleted
Actual Enrollment33
Ages18 Years - N/A
Accepts Healthy VolunteersNo
Eligibility Criteria

Inclusion Criteria:

- surgical biopsy od the peritoneal tumor with frozen samples

- age > 18 years old

Exclusion Criteria:

- absence of peritoneal mesothelioma

- absence of frozen samples

Administrative Information
Responsible PartySponsor
SponsorHospices Civils de Lyon
Verification DateJuly 2016
Mesothelioma Doctors by State
  • Breaking News
  • Emerging Clinical Trials
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog



Terry McCann: Olympic Wrestler, Reformer and Mesothelioma Warrior

What Does Cancer Remission Mean?

Diagnosing Diffuse Mesothelioma with Novel Biomarker CD47

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: